Skip to main content

Belite Bio, Inc 6-K, filed Nov 20, 2026

Belite Bio, Inc (BLTE)

6-K 2026-11-20 For: 2026-11-20
View Original
Added on November 21, 2026

About this 6-K

Belite Bio, Inc filed this 6-K on November 20, 2026.

The FDA extended the review period for the tinlarebant New Drug Application for Stargardt disease type 1 by three months, moving the PDUFA action date to May 12, 2027. If no major deficiencies are identified, the FDA plans to communicate proposed labeling requests by April 12, 2027. AI summary